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TcTLE is a nonamer peptide from Trypanosoma cruzi KMP-11 protein that is conserved
among different parasite strains and that is presented by different HLA-A molecules from
the A2 supertype. Because peptides presented by several major histocompatibility complex
(MHC) supertypes are potential targets for immunotherapy, the aim of this study was to
determine whether MHCmolecules other than the A2 supertype present the TcTLE
peptide.
Methodology/Principal Findings
From 36 HLA-A2-negative chagasic patients, the HLA-A genotypes of twenty-eight patients
with CD8+ T cells that recognized the TcTLE peptide using tetramer (twenty) or functional
(eight) assays, were determined. SSP-PCR was used to identify the A locus and the allelic
variants. Flow cytometry was used to analyze the frequency of TcTLE-specific CD8+ T
cells, and their functional activity (IFN-γ, TNFα, IL-2, perforin, granzyme and CD107a/b pro-
duction) was induced by exposure to the TcTLE peptide. All patients tested had TcTLE-spe-
cific CD8+ T cells with frequencies ranging from 0.07–0.37%. Interestingly, seven of the
twenty-eight patients had HLA-A homozygous alleles: A*24 (5 patients), A*23 (1 patient)
and A*01 (1 patient), which belong to the A24 and A1 supertypes. In the remaining 21
patients with HLA-A heterozygous alleles, the most prominent alleles were A24 and A68.
The most common allele sub-type was A*2402 (sixteen patients), which belongs to the A24
supertype, followed by A*6802 (six patients) from the A2 supertype. Additionally, the
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A*3002/A*3201 alleles from the A1 supertype were detected in one patient. All patients pre-
sented CD8+ T cells producing at least one cytokine after TcTLE peptide stimulation.
Conclusion/Significance
These results show that TcTLE is a promiscuous peptide that is presented by the A24 and
A1 supertypes, in addition to the A2 supertype, suggesting its potential as a target for
immunotherapy.
Introduction
Chagas disease is a neglected tropical disease that is caused by the flagellated protozoan parasite
Trypanosoma cruzi and that is primarily transmitted by blood-sucking triatomines [1].
Approximately 10 million people are infected worldwide, with approximately 40,000 new cases
occurring every year, and the estimated burden of this disease in terms of disability-adjusted
life years (DALYs) is 586,000 [1,2]. After the acute phase, 70–80% of infected people remain
asymptomatic throughout their lives, whereas the other 20–30% develop chronic cardiac or
digestive diseases, which can lead to death [1,2]. Unfortunately, beyond vector control mea-
sures, no prophylactic measures currently exist, and the available treatments are not only toxic
but also have not been proven to be effective in cases of chronic chagasic patients [1,2].
CD8+ T cells are a critical component of the protective immune response against the intra-
cellular parasite T. cruzi [3]. The depletion of CD8+ T cells in animal models of T. cruzi acute
infection demonstrated the role of these cells in infection control. For example, in CD8+ T cell-
depleted mice, the disease develop faster, and these animals have higher parasitemia levels than
wild-type infected mice [4–8]. CD8+ T cell activation occurs when cells specifically recognize
short peptides (8 to 10 amino acids in length), which are usually derived from intracellular pro-
teins and which are presented in the context of the major histocompatibility complex class I
(MHC I) molecules [9–11]. Whereas peptide binding to MHC I molecules occurs through an
interaction between the side chains of the peptide amino acids and the binding pockets of the
MHC I molecule, the peptide-binding affinity is usually determined by an interaction between
the amino acids located on the N- and C-termini of the peptide with the B and F pockets of the
class I molecules [12,13]. Class I molecules are grouped into diverse clusters or supertypes that
share similarities in their peptide-binding pockets. Thus, HLA supertypes are defined as a set
of alleles with potentially similar binding pockets that allow the binding of related peptides
[13,14]. At least nine MHC class I supertypes have been described: A1, A2, A3, A24, B7, B27,
B44, B58 and B62 [13–15].
The frequencies of HLA alleles vary greatly among different populations; thus, obtaining
knowledge regarding these alleles is a critical step in the development of potential therapeutic
or prophylactic immune strategies that require population-wide coverage. In this context, pro-
miscuous peptides, which are defined as peptides that can be presented by different HLA mole-
cules belonging to the same MHC [16] or even different MHC supertypes, are attractive targets
for immunotherapy [17–20].
Our group recently reported that the TcTLE peptide (previously named K1 peptide) from the
KMP-11 protein of T. cruzi is a HLA-A0201-restricted peptide [21]. This peptide is recognized
during the natural course of the disease and is presented by HLA-Amolecules of the A2 supertype,
such as HLA-A0205, HLA-A0222, HLA-A0226, HLA-A0259 and HLA-A0287 [22].
In the present study, the HLA-A2-restricted TcTLE peptide was observed to be presented
by other HLA-A supertypes and able to induce functional activity in CD8+ T cells from these
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chagasic patients. Indeed, the finding that A24, A23 and A01 homozygous patients have
TcTLE-specific CD8+ T cells demonstrated that several MHC supertypes present this peptide.
TcTLE peptide-specific CD8+ T cells from non-HLA-A2 chagasic patients were also shown to
be able to produce gamma interferon (IFN-γ), tumoral necrosis factor (TNFα), interleukin-2




Thirty-six chagasic patients from endemic areas of Colombia, including 13 males and 23
females with ages ranging from 19–76 years, were included in the study. All the subjects were
recruited and clinically evaluated at the Hospital Universitario San Ignacio, Fundación Abood
Clínica Shaio or Instituto Nacional de Salud in Bogotá, Colombia. All subjects were anti-T.
cruzi antibody-positive according to both indirect immunofluorescence immunoassay (IFI)
and enzyme-linked immunosorbent assay (ELISA) [23]. All chagasic patients were classified
according to the Kuschnir grading system [24]. Fifteen patients were classified as non-cardiac
chagasic patients or G0 stage (normal electrocardiogram (ECG) results), and twenty-one were
classified as cardiac chronic chagasic patients (CCC) with different degrees of disease severity
as follows: seven G1 with abnormal ECG results, seven G2 with abnormal ECG results and car-
diac enlargement and seven G3 with abnormal ECG results, cardiac enlargement and clinical
signs of heart failure. The group of healthy donors (HDs) consisted of fourteen seronegative
individuals with similar ages to the chagasic donors who have always resided in non-endemic
areas and who exhibited normal ECG results and clinical examination. All donors were volun-
teers, and they signed informed consent forms before being included in the study.
Approximately 20 mL of blood was collected from each individual by venipuncture as fol-
lows: 10 mL was collected in heparinized tubes for isolating peripheral blood mononuclear
cells (PBMCs) by Ficoll-Paque PLUS density gradient centrifugation (GE Healthcare Biosci-
ence, Uppsala, Sweden), 4 mL was collected in EDTA tubes for DNA extraction and 6 mL was
collected for serological tests (Vacutainer, Becton-Dickinson, San José, CA, USA).
Ethics statement
This work was approved by the Research and Ethics Committees of the Facultad de Ciencias
from the Pontificia Universidad Javeriana (6th April 2011 and 17th June 2009 CIEs). All adult
subjects who participated in the study read, accepted and signed the informed consent form.
HLA-A2 typing by flow cytometry
HLA-A2 typing was performed as previously described [22]. Briefly, 100 μL of peripheral blood
was incubated with 0.25 μg of anti-HLA-A2 FITC antibody (clone BB7.2; BD Pharmingen, San
Diego, CA, USA) for 20 minutes at 4°C [25]. After adding 500 μL of 1X lysis buffer (BD Bioscience,
San José, CA, USA), the cells were incubated for 15 minutes at room temperature. Finally, the cells
were washed with 1X phosphate-buffered saline (PBS; Eurobio, Les Ulis, France), and data were
collected using a FACSAria II flow cytometer (BD Immunocytometry Systems, San José, CA,
USA). The data were analyzed with FlowJo 9.3.2 software (Tree Star, Inc., Ashland, OR, USA).
HLA typing by SSP Unitray
HLA-A locus evaluation was performed using a commercial PCR kit based on sequence-spe-
cific primers (SSP-PCR) according to the manufacturer’s instructions (Biotest, Landsteinerstr,
Promiscuous Non-HLA-A2 Recognition of TcTLE
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Dreieich, Germany). Genomic DNA was extracted from each patient’s peripheral blood using
a GFX genomic blood DNA purification kit (Amersham Biosciences, Piscataway, NJ, USA).
PCRs were conducted in a Stomacher 3500 Thermal Cycler PTC-100 (MJ Research, Inc.,
Watertown, MA, USA). The amplified products were resolved via 2% agarose gel electrophore-
sis and visualized following ethidium bromide staining. The amplified fragments were analyzed
using UnimatchTM 4.01 software (Invitrogen, Brown Deer, WI, USA). Once the alleles present
in each individual were determined, medium-high-resolution typing was performed using
A01, A03, A11, A19, A23, A24 or A68 SSP Unitray kits (Dynal Invitrogen Corporation,
Brown Deer, WI, USA) according to the manufacturer’s protocols.
Tetramer staining
HLA-A2 PE-labeled tetramers loaded with TcTLE peptide (TLEEFSAKL), derived from T.
cruzi KMP-11 protein [22], and also HLA-A2 PE-labeled tetramers with a modified Flu-MP
peptide (Flu-MP; GILGFVTTL) derived from the influenza virus matrix protein [22,26], and
a modified CMV pp65 peptide (CMV; DLSPMVATV), employed as controls, were produced
by the National Institute of Health (NIH) Tetramer Facility (Atlanta, GA, USA). In total,
1 × 106 PBMCs per tube were stained with 0.5 μg/mL tetramers and anti-CD3-PerCP (clone
SK7) and anti-CD8-FITC (clone SK1) conjugates (BD Biosciences, San José, CA, USA) for 20
minutes in the dark at room temperature. After the cells were washed with staining buffer (1%
fetal bovine serum in 1X PBS), they were resuspended in 500 μL of 1X PBS. At least 50,000
events gated for CD3+ CD8+ T cells were acquired and analyzed using a FACSAria II flow
cytometer (BD Immunocytometry Systems) and FlowJo 9.3.2 software (Tree Star, Inc.). The
gating strategy is shown in Fig 1A and 1B. The cut-off point for HLA-A2/TcTLE tetramer
CD8+ T cells was established at 0.063% after determining the average background value of
K1-specific CD8+ T cells from HD (0.027%) plus three standard deviations (0.012%). A cut-off
point for HLA-A2/Flu-MP and HLA-A2/CMV tetramer CD8+ T cells was fixed at 0.1% [26].
CD8+ T cell cytokine production and degranulation assays by flow
cytometry
To assess T cell function, 1 × 106 PBMCs were cultured with the TcTLE peptide (10 μg/mL) for
6 hours at 37°C and 5% CO2 in the presence of CD28 (1 μg/mL) and CD49d (1 μg/mL). After
the cells were incubated for one hour, brefeldin A (1 μg/mL) and monensin (1 μg/mL) (BD
Pharmingen) were added to the cultures. PBMCs were labeled with Live/Dead Fixable Aqua
for 20 minutes in the dark at room temperature. Then, the cells were stained with anti-CD3
Pacific Blue (clone UCHT1) and anti-CD8 APC-H7 (clone SK1) monoclonal antibodies (BD
Biosciences). The cells were permeabilized with Cytofix/Cytoperm (BD Pharmingen) and
stained with anti-IL-2 PerCP-Cy5.5 (clone MQ1-17H12; BD Biosciences), anti-IFN-γ Alexa
Fluor 700 (clone B27; BD Biosciences, San Jose, CA, USA), anti-TNFα APC (clone 6401.1111;
BD Biosciences), anti-Perforin PE (clone B-D48; Abcam, Cambridge, MA, USA) and anti-
Granzyme B Alexa Fluor 647 (clone GB11) conjugates (BD Biosciences) for 30 minutes at 4°C.
To evaluate potential cytotoxic activity, anti-CD107a (clone H4A3) and CD107b FITC (clone
H4B4) conjugates (BD Biosciences) were added to the PBMCs before stimulation. In each
experiment, non-stimulated cells were used as a negative control, and staphylococcal entero-
toxin B (SEB) (1.5 μg/mL) (Sigma-Aldrich, Saint Louis, MO, USA) was used as a positive con-
trol (S1 and S2 Tables). At least 50,000 events gated on live CD3+ CD8+ T cells were acquired
using a FACSAria II flow cytometer (BD Immunocytometry Systems) and analyzed with
FlowJo 9.3.2 software (Tree Star, Inc.). A positive cytokine response was defined by subtracting
the background of cytokine production (cells cultured without antigen) and obtaining a value
Promiscuous Non-HLA-A2 Recognition of TcTLE
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Fig 1. Flow cytometry gating strategy and frequency of TcTLE-specific CD8+ T cells.Dot plots representative of the analysis of an HLA-A2-negative
chagasic patient. (A) Lymphocytes were selected, and cell doublets were excluded from the analysis for the identification of CD8+ T cells based on the
forward scatter area (FSC-A) and forward scatter height (FSC-H) (singlet 1), forward scatter width (FSC-W) and forward scatter height (FSC-H) (singlet 2),
and side scatter width (SSC-W) and SSC-H characteristics (singlet 3). Finally, live CD3+ CD8+ cells were selected. (B) Selection of TcTLE peptide-specific
CD8+ T cells by soluble tetramer assay. (C) Frequency of TcTLE peptide-specific CD8+ T cells from 20 HLA-A2-negative chronic chagasic patients. The cut-
off point, which was fixed at 0.063, is indicated by the dotted line.
doi:10.1371/journal.pone.0150996.g001
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exceeding 0.05%; this frequency corresponds to the average frequency of CD8+ T cells produc-
ing cytokines from HDs cultured with the TcTLE peptide plus 3 standard deviations. Multi-
functional analysis was performed using the Boolean gating strategy and visually represented
with Pestle version 1.7 and SPICE software version 5.3 (provided by the NIH, Bethesda, MD,
USA) [27].
Statistical analysis
Differences between two groups were assessed using the Mann-Whitney test. Tests were two-
tailed, and differences were considered statistically significant when p< 0.05. GraphPad Prism
version 6.0 for Mac OS X (GraphPad Software, San Diego, CA, USA) statistical software was
used for statistical analyses.
Results
TcTLE peptide: An epitope presented by several HLA-A supertypes
Previous studies of the KMP-11-derived TcTLE peptide revealed that it is efficiently processed,
presented and recognized by CD8+ T cells in the context of the HLA-A0201 molecule during
the natural course of Chagas disease [22,28]. In addition, by applying a tetramer staining
approach, the TcTLE peptide was observed to also be presented by other HLA-A2 alleles
because it was recognized by CD8+ T cells from infected patients in the context of the
HLA-A0205, HLA-A0222, HLA-A0226, HLA-A0259 and HLA-A0287 alleles [22]. Unex-
pectedly, when examining the frequency and functionality of TcTLE peptide-specific CD8+ T
cells in a broader number of patients, twenty-eight of the thirty-six analyzed HLA-A2-negative
chagasic patients were found to have CD8+ T cells that recognized the TcTLE peptide. Tetra-
mer staining revealed that twenty of these patients had CD8+ T cells that were able to bind to
the HLA-A2/K1-peptide tetramer at percentages ranging from 0.07–0.37% (median = 0.16%)
(Fig 1C and Table 1). The CD8+ T cells of the remaining eight patients were evaluated accord-
ing to cytokine production and cytotoxic activity and were found to recognize the TcTLE pep-
tide and to respond by producing cytokines or by exhibiting cytotoxic activity (see below). In
order to evaluate the frequency of specific-CD8+ T cells of the irrelevant peptides, used as con-
trols, the frequency of Flu-MP and CMV specific-CD8+ T cells was determined in the same
assay conditions and with cells from the same patients. Indeed, it was found that although 11
out of 28 chagasic patients presented frequencies to both, TcTLE and Flu-MP peptides, 8 out
of 28 only presented frequencies to TcTLE peptide and one patient (KT-059) only presented
frequencies to Flu-MP. Additionally, the frequency of CD8+ T cells specific to CMV was
determined in the QX-036 and QX-039 patients. The results showed that while the QX-036
patient had frequencies of CD8+ T cells specific to TcTLE and CMV peptides, the QX-039
patient only had frequencies of TcTLE peptide-specific CD8+ T cells. Together, these results
demonstrate the specificity of the response.
Based on these results, the HLA-A genotype of these twenty-eight patients (Table 1) was
confirmed by HLA-A locus PCR-SSP molecular typing. Seven of the twenty-eight (25%) tetra-
mer- or cytokine/cytotoxic-positive chagasic patients had HLA-A homozygous alleles for A24
(five patients), A23 (one patient), and A01 (one patient) (Table 1). Among the twenty-one
HLA-A heterozygous patients, the most common alleles were A24 (57.1%) and A68 (38.0%),
followed by A31, A11, A23, and A29 (20% each) (Fig 2A and Table 1). All eight tetramer-
negative patients showed a heterozygous pattern, with the most common allele being A24
(75% of the donors), followed by A31 (37.5%) and A68 (37.5%) (Table 1). Two individuals of
the HD group had HLA-A24 homozygous alleles, and A24 was the most common allele
(57.0% of the donors) observed in a similar proportion of the chagasic patients (Table 1).
Promiscuous Non-HLA-A2 Recognition of TcTLE
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Table 1. Characteristics of HLA-A2- individuals, the frequency of CD8+ T cells specific for the TcTLE peptide, and low-resolution typing of HLA-A
alleles.




KT-035 HD Bogotá—Cundinamarca F 37 0.03 0.03 ND A23/A24
KT-094 HD Bogotá—Cundinamarca M 67 0.03 0.02 ND A24/A68
KT-096 HD Roldanillo—Valle F 61 0.02 0 ND A01/A24
KT-097 HD Barranquilla—Atlántico F 19 0.04 0.03 ND A24/A24
KT-098 HD Bogotá—Cundinamarca F 58 0.01 0 ND A30/A33
KT-099 HD Bogotá—Cundinamarca M 44 0.01 0.04 ND A03/A68
KT-100 HD Bogotá—Cundinamarca F 39 0.02 0.05 ND A24/A32
KT-101 HD Bogotá—Cundinamarca F 65 0.04 0.01 ND A24/A30
CS-005 HD Pasto—Nariño F 26 0.04 ND ND A29/A31
CS-007 HD Bogotá—Cundinamarca F 47 ND ND ND A24/A24
CS-016 HD Bogotá—Cundinamarca F 41 ND ND ND A24/A68
CS-017 HD Bogotá—Cundinamarca M 44 ND ND ND A11/A33
CS-018 HD Bogotá—Cundinamarca F 44 ND ND ND A30/A33
CS-040 HD Medellín—Antioquia M 58 ND ND ND A03/A30
KT-034 G0 Moniquirá—Boyacá M 37 0.37 0.29 ND A23/ A68
QX-035 G0 Sucre—Santander F 39 0.28 0.09 ND A24/ A30
QX-036 G0 Gachalá—Cundinamarca F 44 0.16 0.09 0.26 A24/ A68
QX-039 G0 Apulo—Cundinamarcaa F 54 0.14 0.08 0.03 A24/ A29
KT-044 G0 Bogotá—Cundinamarca M 19 0.27 0.25 ND A24/A24
KT-062 G0 Paéz—Boyacá F 28 0.04 0.05 ND A11/A11
KT 063 G0 Somondoco—Boyacá M 57 0.15 0.06 ND A11/ A68
KT-069 G0 Capitancio—Santander M 45 0.02 0.05 ND A24/A31
KT-073 G0 Miraﬂores—Boyacá M 42 0.03 0.04 ND A24/A30
KT-081 G0 Paéz—Boyacá F 56 0.04 0.09 ND A24/A68
KT 087 G0 Bolivar—Santander F 71 0.13 0.08 ND A24/ A68
KT 088 G0 Miraﬂores—Boyacá M 60 0.13 0.09 ND A24/A24
KT 043 G1 Soata—Boyacá M 61 0.22 0.33 ND A23/ A68
KT-050 G1 Miraﬂores—Boyacá F 45 0.04 0.05 ND A24/A31
KT 067 G1 Ibagué—Tolima M 41 0.24 0.22 ND A01/ A31
KT-068 G1 Gallegos—Santander F 59 0.05 0.04 ND A31/A68
KT-071 G1 Rondón—Boyacá M 38 0.03 0.05 ND A24/A32
KT 072 G1 Yopal—Casanare F 52 0.09 0.18 ND A23/A23
KT 078 G1 El Engaño—Cundinamarca F 60 0.19 0.18 ND A01/ A29
KT-039 G2 Soatá—Boyacá F 67 0.27 0.23 ND A24/A24
KT-040 G2 Sutatenza—Boyacá F 76 0.07 0.04 ND A30/ A32
KT-053 G2 Pajarito—Boyacáa F 44 0.13 0.12 ND A24/ A68
KT-059 G2 San José de Pare—Boyacá F 49 0.06 0.11 ND A03/A32
KT-061 G2 Berbeo—Boyacá M 65 0.22 0.15 ND A24/ A31
KT-074 G2 San Joaquín—Santander M 46 0.09 0.09 ND A11/ A24
KT-051 G3 Guamo—Tolima F 58 0.15 0.26 ND A11/ A23
KT-058 G3 Armero—Tolima F 39 0.07 0.08 ND A24/ A68
QX-062 G3 Zetaquirá—Boyacá F 70 0.25 0.22 ND A24/ A29
QX-018 G0 Tablón—Togui-Boyacáa F 35 ND b ND ND A24/A24
QX-045 G0 Santander—Belleza F 32 ND b ND ND A01/A01
(Continued)
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To determine the relationship between the HLA allele supertype and TcTLE recognition,
tetramer- (twenty) or cytokine/cytotoxic-positive (eight) patients and healthy controls (twelve)
were subjected to medium-high-resolution molecular typing (Table 2). Seven HLA-A homozy-
gous patients were identified: five A2402, one A2301 and one A0101. Note that the A2402
and A2301 alleles belong to the A24 supertype and that the A0101 allele belongs to the A1
supertype (Fig 2B and Table 2). Additionally, 14 HLA-A heterozygous patients were found to
have the A2402 allele (57.1%) in the absence of A6802 (Fig 2B), which belongs to the A2
supertype, the same supertype of the A0201 allele in which the TcTLE peptide presentation
was first described. Indeed, the A2402 allele was the most frequent allele in the A24 individu-
als (94.1%), (Fig 2B and Table 2). Additionally, two A1 supertype-allele members were detected
in chagasic patients: one patient had A3002/A3201 and two patients had A0101 alleles, in
the absence of any A2 or A24 supertype members (Fig 2B and Table 2). In contrast, six of the
eight A68 patients were A6802.
Table 1. (Continued)




QX-050 G0 Chima—Santander F 39 ND b ND ND A03/A30
QX-052 G2 Chitaraque—Boyacá F 65 ND b ND ND A29/A31
QX-002 G3 Sabana larga—Casanare M 65 ND b ND ND A24/A31
QX-031 G3 Soatá—Boyacá F 55 ND b ND ND A24/A24
QX-051 G3 Chitaraque—Boyacá F 55 ND b ND ND A11/A24
QX-054 G3 Fómeque—Cundinamarca M 57 ND b ND ND A24/A68
* Indicates that peptides have a modiﬁcation compared to original peptide
a Indicates people who continued living in endemic areas. HDs: healthy donors; ND: not determined.
b Indicates patients who have TcTLE-speciﬁc CD8+ T cells with cytokine production after TcTLE peptide stimulation.
Positive frequencies of speciﬁc CD8+ T cells are indicated in bold.
doi:10.1371/journal.pone.0150996.t001
Fig 2. HLA typing of chronic chagasic patients with TcTLE-specific CD8+ T cells. HLA-A types (A) and sub-types (B) of chronic chagasic patients with
TcTLE peptide-specific CD8+ T cells. The figure shows the number of patients with each HLA-A type and sub-type.
doi:10.1371/journal.pone.0150996.g002
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Functional activity of TcTLE peptide-specific CD8+ T cells in
HLA-A2-negative (A24 and A1 supertypes) chagasic patients
To evaluate the functional activity of TcTLE peptide-specific CD8+ T cells from HLA-A2-nega-
tive patients with A24 or A1 supertypes, CD8+ T cells from twelve chronic chagasic patients

















KT-035 A*23 A*2301 A24 KT-058 A*24 A*2402 A24
A*24 A*2402 A24 A*68 A*6802 A2
KT-094 A*24 A*2403 A24 KT-061 A*24 A*2402 A24
A*68 A*6801 A3 A*31 A*3101 A3
KT-096 A*01 A*0101 A1 KT-063 A*11 A*1101 A3
A*24 A*2402 A24 A*68 A*6802 A2
KT-097 A*24 A*2414 A24 KT-067 A*01 A*0101 A1
A*24 A*2414 A24 A*31 A*3109 A3
KT-098 A*30 A*3002 A1 KT-072 A*23 A*2301 A24
A*33 A*3301 A3 A*23 A*2301 A24
KT-099 A*03 A*0301 A3 KT-074 A*11 A*1101 A3
A*68 A*6801 A3 A*24 A*2402 A24
KT-100 A*24 A*2404 Unclassiﬁed KT-078 A*01 A*0101 A1
A*30 A*3001 A1/A3 A*29 A*2904 Unclassiﬁed
KT-101 A*24 A*2402 A24 KT-087 A*24 A*2402 A24
A*30 A*3001 A1/A3 A*68 A*6801 A3
CS-005 A*29 A*2903 A1/A24 KT-088 A*24 A*2402 A24
A*31 A*3101 A3 A*24 A*2402 A24
CS-007 A*24 A*2402 A24 QX-002 A*24 A*2402 A24
A*24 A*2402 A24 A*31 A*3101 A3
CS-016 A*24 A*2402 A24 QX-018 A*24 A*2402 A24
A*68 A*6801 A3 A*24 A*2402 A24
CS-017 A*11 A*1101 A3 QX-031 A*24 A*2402 A24
A*33 A*3301 A3 A*24 A*2402 A24
CS-018 A*30 A*3001 A1/A3 QX-035 A*24 A*2402 A24
A*33 A*3301 A3 A*30 A*3010 Unclassiﬁed
CS-040 A*03 A*0301 A3 QX-036 A*24 A*2402 A24
A*30 A*3004 A1 A*68 A*6801 A3
KT-034 A*23 A*2301 A24 QX-039 A*24 A*2402 A24
A*68 A*6802 A2 A*29 A*2902 A1/A24
KT-039 A*24 A*2402 A24 QX-045 A*01 A*0101 A1
A*24 A*2402 A24 A*01 A*0101 A1
KT-040 A*30 A*3002 A1 QX-050 A*03 A*0301 A3
A*32 A*3201 A1 A*30 A*3001 A1/A3
KT-043 A*23 A*2301 A24 QX-051 A*11 A*1101 A3
A*68 A*6802 A2 A*24 A*2402 A24
KT-044 A*24 A*2402 A24 QX-052 A*29 A*2902 A1/A24
A*24 A*2402 A24 A*31 A*3101 A3
KT-051 A*11 A*1101 A3 QX-054 A*24 A*2402 A24
A*23 A*2301 A24 A*68 A*6802 A2
KT-053 A*24 A*2414 A24 QX-062 A*24 A*2402 A24
A*68 A*6802 A2 A*29 A*2902 A1/A24
doi:10.1371/journal.pone.0150996.t002
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were analyzed using six functional parameters after TcTLE peptide stimulation. Thus, the
intracellular production of three cytokines (IFN-γ, TNFα and IL-2) and the potential cytotoxic
activity, which was measured by evaluating CD107a/b expression as a marker of degranulation
and intracellular perforin and granzyme B expression, were assessed.
The flow cytometric analysis strategy is shown in Fig 3A. Analysis of individual cytokine
production showed that all chagasic patients had CD8+ T cells that produced at least one of
Fig 3. Polyfunctional profile of TcTLE-specific CD8+ T cell responses. (A) Functional cellular analysis of parasite-specific CD8+ T cells after stimulation
with the TcTLE peptide. Gates were applied to identify cytokine-positive cells; these were defined according to the unstimulated samples for each subject. (B)
The functional profiles of CD8+ T cells of HLA-A2-negative chagasic chronic patients were determined using a five-function detection method for CD107a/b,
perforin, IFN-γ, IL-2 and TNFα after stimulation with the TcTLE peptide. The pie charts show the median percentages of responding CD8+ T cells grouped
according to the number of simultaneous functions performed and color-coded depending on the functional profile. (C) Frequency of TcTLE-specific CD8+ T
cells producing fifteen distinct combinations of five functions in non-CCC (white bars) and CCC patients (black bars). The results are shown as box-and-
whisker (min-to-max) plots with median percentages of responding CD8+ T cells.
doi:10.1371/journal.pone.0150996.g003
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these cytokines (Table 3). As shown, one of twelve (8.3%) patients showed CD8+ T cells with
only one or two effector functions, two patients (16.6%) showed three functions, three patients
(25%) exhibited four functions, and four patients (33.3%) presented positive results for five of
the six molecules tested. Cytokine-producing CD8+ T cells were not detected in HDs after anti-
genic stimulation (Table 3).
Subsequently, CD8+ T cell polyfunctionality, which refers to simultaneous cytokine produc-
tion and cytotoxic activity by a single cell, was evaluated. Five effector functions (IFN-γ, TNFα,
IL-2, perforin and CD107a/b) were measured after peptide stimulation. No TcTLE-specific
CD8+ T cells exhibited all five effector functions (Fig 3B and 3C) in non-cardiac or CCC
patients. In contrast, the peptide-specific CD8+ T cells of CCC and non-CCC patients pre-
sented positive results for four, three and two of these functions (Fig 3C). Generally, non-CCC
patients had a higher frequency of CD8+ T cells exhibiting four or two functions than those
with cardiac manifestations. Thus, the most predominant profile including four positive effec-
tor functions was CD107a/b, IFN-γ, perforin and TNFα. In this case, although no significant
differences were found, non-CCC patients tended to have more polyfunctional CD8+ T cells
than did CCC patients. In contrast, specific CD8+ T cells with three positive functions were
observed at similar frequencies in both patient groups. Although significant differences were
not observed, the expression of IFN-γ and perforin was more frequent in non-CCC patients,
whereas the production of CD107a/b and perforin was more frequent in CCC patients. Regard-
ing monofunctional cells, TNFα and IFN-γ were the major cytokines produced by CD8+ T
cells from non-CCC patients, and perforin was the most predominant functionality detected in
CD8+ T cells from CCC patients (Fig 3C). Overall, these results demonstrate that TcTLE pep-
tide-specific CD8+ T cells from HLA-A2 negative chagasic patients (specifically A24 and A1
supertypes) are functional.
Table 3. Frequency of cytokine response and cytotoxic activity after TcTLE peptide stimulation.
Patient code Genotype Clinical
status
Frequency of cytokine production after TcTLE peptide stimulation a
IFN-γ TNFα IL-2 Perforin Granzyme B CD107a/b
CS-005 A*2903/A*3101 HD 0 0.03 0.00 0.00 0.00 0.00
CS-007 A*2402/A*2402 HD 0.01 0.00 0.03 0.00 0.00 0.04
CS-016 A*2402/A*6801 HD 0.04 0.00 0.00 0.00 0.00 0.00
CS-017 A*1101/A*3301 HD 0.01 0.00 0.00 0.00 0.00 0.00
CS-018 A*3001/A*3301 HD 0.01 0.00 0.00 0.00 0.00 0.00
CS-040 A*0301/A*3004 HD 0.02 0.01 0.00 0.00 0.03 0.04
QX-031 A*2402/A*2402 G0 0.57 0.00 0.03 0.00 0.00 0.00
QX-035 A*2402/A*3010 G0 0.03 0.90 0.00 3.70 2.40 0.07
QX-036 A*2402/A*6801 G0 0.00 0.07 0.01 0.00 1.10 0.60
QX-039 A*2402/A*2902 G0 0.47 0.15 0.02 8.60 2.30 0.22
QX-045 A*0101/A*0101 G0 0.09 0.19 0.09 2.50 0.80 0.00
QX-050 A*0301/A*3001 G0 0.36 0.00 0.11 2.45 0.00 0.00
QX-052 A*2902/A*3101 G2 0.62 0.56 0.07 3.60 0.07 0.76
QX-002 A*2402/A*3101 G3 0.10 0.00 0.09 2.37 5.70 0.41
QX-031 A*2402/A*2402 G3 0.45 0.52 0.40 0.00 0.00 0.18
QX-051 A*1101/A*2402 G3 0.59 0.09 0.32 0.00 0.10 0.00
QX-054 A*2402/A*6802 G3 0.00 0.33 0.00 0.03 4.80 0.00
QX-062 A*2402/A*2902 G3 0.49 0.00 0.10 1.29 2.60 0.50
a A positive cytokine response (bold) was deﬁned as > 0.05% after background (without antigen) subtraction.
doi:10.1371/journal.pone.0150996.t003
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Discussion
Using experimental animal models, CD8+ T cells were demonstrated to be essential in control-
ling the spread of T. cruzi infection [3–8]. In addition, CD8+ T cells specific to T. cruzi antigens
play an important role in protecting against T. cruzi infection in humans, and most of their epi-
topes are restricted to the HLA-A0201 allele. Thus, some A2-restricted epitopes have been
extensively studied to explore their use in vaccine or immunotherapy design [29–32]. One of
these epitopes, the TcTLE peptide, has been reported to be a promiscuous epitope presented in
several alleles from the A2 supertype [22, 27]. In the in-depth study described here, the TcTLE
peptide was also presented by other HLA-A alleles belonging to the A1 and A24 supertypes.
Consequently, the functional activity of the TcTLE-specific CD8+ T cells from these HLA-A2--
negative chronic chagasic patients was analyzed in terms of frequency and functionality, and
its correlation with patient haplotype was assessed.
Several reports have described promiscuous T cell epitopes derived from infectious organ-
isms, such as the dengue and Epstein-Barr (EBV) viruses, which are presented by more than
one HLA-A allele and even by different HLA-A supertypes [17,18]. For example,Mongkolsa-
paya et al. [18] reported the promiscuous presentation of an A2402-restricted epitope (from
the A24 supertype) and an A1101 allele, classified in the A3 supertype. Additionally, Liu et al.
[16] described various influenza A virus peptides capable of being presented by alleles belong-
ing to the A24 and A3 supertypes. In this study, the promiscuous recognition of the TcTLE
peptide among CD8+ T cells from chagasic donors having A1, A2 and A24 supertypes was
detected. This phenomenon of presentation by different MHC supertypes has also been identi-
fied in tumor-derived peptides [20,33].
Peptides from different pathogens presented in the context of homozygous HLA-A alleles
confirmed the antigen presentation by alleles belonging to different supertypes. InMycobacte-
rium tuberculosis, peptides derived from the TB10.4 protein are presented by homozygous
HLA-A3001 and A3002 alleles, which are recognized by peptide-specific CD8+ T cells from
patients with active tuberculosis [34]. Cytomegalovirus AYAQKIFKIL- and PYLFWLAAI
EBV-derived-peptides are presented by both HLA A2301 and A2402 alleles and generate a
CTL response [35]. Similarly, the TcTLE peptide was presented by different homozygous
HLA-A alleles, such as A0101 from the A1 supertype and A2301 and A2402 from the A24
supertype.
Although HLA-B and HLA-C alleles may also bind and present the TcTLE peptide, our
results indicate that the TcTLE peptide was able to be presented by the HLA-A6802 allele
from the A2 supertype, the supertype in which this peptide was originally described, and by
other HLA-A alleles belonging to other supertypes, such as HLA-A0101, A3002, A3201 and
A1101 of the A1 supertype) and A2301 and A2402 of the A24 supertype, which all gener-
ated measurable specific CD8+ T cell responses in T. cruzi-infected patients.
Using tetramer staining, CD8+ T cells from fifteen of nineteen (78.9%) HLA-A2-positive
chagasic patients were previously shown to recognize the TcTLE peptide with tetramer fre-
quencies ranging from 0.09% to 0.34% [22]. Similar percentages and frequencies are reported
here: twenty of twenty-eight (71.4%) HLA-A2-negative chagasic patients had tetramer fre-
quencies of 0.07-0.37%. Consequently, antigen-specific CD8+ T cells from chronic chagasic
patients recognized the TcTLE peptide independent of their HLA-A supertype, which indi-
rectly indicates that the TcTLE peptide is presented by HLA-A alleles other than HLA-A2.
Taken into account the published data [12,36–41] summarized in Table 4, the binding of the
TcTLE (TLEEFSAKL) peptide to other alleles of the HLA-A1 and HLA-A24 supertypes is pos-
sible because the leucine (L) at 2 and 9 primary anchors positions of the TcTLE peptide bound
to the B and F pockets of the MHC molecules of these supertypes (Table 4). Regarding the Flu-
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MP peptide, previously we described that it is recognized by several alleles from the A2 super-
type. The results of this work, suggest that this peptide could be also presented by other alleles
from different supertypes. This possibility can be explained by the fact that the isoleucine (I) at
2 position and the leucine (L) at 9 position of the Flu-MP (GILGFVTTL) peptide, fits in the B
and F pockets of the alleles of these supertypes, respectively (Table 4). However, this hypothesis
should be confirmed.
The analysis of individual cytokine production showed that all HLA-A2-negative chagasic
patients had CD8+ T cells that produced at least one of the cytokines tested. This finding,
together with the existence of polyfunctional CD8+ T cells in these HLA-A2-negative chagasic
patients, allow us to propose that these CD8+ T cells from chronic chagasic patients belonging
to the A24 and A1 supertypes are fully functional. Regarding the heterogeneous phenotype of
the CD8+ T cells exhibiting the antagonistic functional activities associated with protection or
pathogenesis, for instance, IFN-γ versus perforin [3], a larger sample size is needed to reach a
conclusion concerning the role of heterogeneous phenotypes in disease control or progression.
A similar requirement is suggested for assessing the role of the polyfunctional CD8+ T cells,
which are usually associated with protection against chronic infections [42,43]. Indeed, recent
results from our group indicate that patients with less-severe disease have a higher frequency
of polyfunctional CD8+ T cells, whereas patients at the advanced stage of the disease have a
higher frequency of monofunctional CD8+ T cells [44]. The fact that the total parasite antigens,
the KMP-11 protein [44] and the TcTLE peptide have revealed that the disease severity in car-
diac chronic chagasic patients could be associated with a low frequency of polyfunctional
CD8+ T cells, suggest that these markers could be evaluated for their use in the prediction of
progression disease in accordance with the polyfunctional potential loss.
The promiscuity of the TcTLE peptide was observed both by soluble tetramers assays and
cytokine production after peptide stimulation. Therefore, the cytokine production and the cyto-
toxic activity results reinforce the findings of TcTLE peptide promiscuity, according to the results
found with tetramers. In addition, the frequency of TcTLE peptide-specific non-CD8+ T cells
was evaluated and no frequencies of non-CD8+ T cells specific to this peptide were found (S1
Fig), finding that the tetramer binding is specific. Taking into account that subjects with ongoing
chronic inflammation/immune stimulation due to chronic infections or inflammatory diseases
are likely to have higher background staining with tetramer reagents, it is important to mention
that we previously reported that patients with non-chagasic chronic heart diseases did not have
significant frequencies of TcTLE peptide-specific CD8+ T cells [45]. However, other approaches
as the use APCs consisting of HLA empty cell lines expressing only the HLA allele of interest
could be used to further explore the specificity of HLA epitope restriction.
The most common HLA-A alleles in the Latin American population are as follows: HLA-
A02 (28%), A24 (11%) and A68 (5%) in Brazil [46,47]; A02 (50%), A24 (14%) and A68
Table 4. Summary of primary anchors influences on the HLA-A2, A1 and A24 supertypes binding affinity.
Supertype Allele(s) Position 2 motif Position 9 motif References
A2 A*0201 LMV [TQAI] VIL [MTA] [12,37–41]
A*6802
A1 A*0101 TI [LMVS] FWY [LV] [36,38–40]
A*3201
A24 A*2402 YF [LMVIT] FI [WLMY] [36,38–40]
A*2301
Amino acids listed in brackets are residues that are tolerated.
doi:10.1371/journal.pone.0150996.t004
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(10%) in Bolivia [48]; A02 (63.4%), A30 (10.2%), A24 (6.6%) and A68 (5.4%) in Peru [49];
and HLA-A02 (25.5%), A24 (23%) and A68 (6.0%) in Colombia [50,51]. Notably, these
reports revealed that more than 45% of the Latin American population have HLA-A02, A24
or A68 HLA alleles; A02 was the original allele restriction reported for the TcTLE peptide
[21,22]. In this work, A24 and A68 alleles were also implicated in TcTLE presentation.
Consequently, a high percentage of the Latin American population has HLA-A alleles
belonging to the A1, A2 and A24 supertypes, which are capable of presenting the TcTLE pep-
tide and of inducing immune responses through effector functions and cytotoxic activities.
Additionally, the TcTLE sequence is conserved among different parasite strains, particularly if
it is also present in the KMP-11 protein from Trypanosoma rangeli, a synanthropic non-
human pathogenic parasite [52]. Taken together, these results reasonably suggest that the
TcTLE peptide, together with other parasite sequences [53,54], could represent a potential tar-
get for vaccine or immunotherapy development against Chagas disease.
In summary, these results demonstrate that the TcTLE peptide epitope is recognized and
presented by different HLA-A alleles from the A2, A24 and A1 supertypes and that it induces
an immune response characterized by cytokine production and cytotoxic activity. This T.
cruzi-derived peptide, which exhibits broad coverage of HLA presentation in the population, is
a potential target for immunotherapy against Chagas disease.
Supporting Information
S1 Fig. Frequency of TcTLE-specific CD8+ T cells and non-CD8+ T cells. Dot plots represen-
tative of the analysis of two HLA-A2-negative chagasic patients. Analysis were made on total
CD3+ T cells to evaluated the frequency of TcTLE-specific CD8+ T cells and non-CD8+ T cells,
and on total CD8+ T cells.
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S1 Table. Frequency of cytokine response and cytotoxic activity after culture without stim-
ulation.
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